Summit Therapeutics (SMMT) Beginning Cash Balance (2022 - 2024)
Summit Therapeutics (SMMT) reported Beginning Cash Balance of $75.5 million for Q4 2024, little changed quarter-over-quarter from $75.5 million in Q3 2024.
Summit Therapeutics (SMMT) Beginning Cash Balance (2022 - 2024) Analysis & Trends
Summit Therapeutics has reported Beginning Cash Balance for 3 years, with the latest figure at $75.5 million in Q4 2024.
- For the quarter ending Q4 2024, Beginning Cash Balance changed N/A year-over-year to $75.5 million; the trailing twelve-month figure through Dec 2025 stood at $151.0 million (changed 0.0% YoY), and the FY2024 full-year result was $100.0 million, up 305.09% from the prior year.
- Beginning Cash Balance for Q4 2024 stood at $75.5 million, roughly flat from $75.5 million in the prior quarter.
- The five-year high for Beginning Cash Balance was $75.5 million in Q3 2024, with the low at $24.7 million in Q1 2023.
- Historically, Beginning Cash Balance has averaged $50.2 million across 3 years, with a median of $50.2 million in 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 75.50 Mn |
| Dec 31, 2024 | 75.50 Mn |
| Sep 30, 2024 | 75.50 Mn |
| Sep 30, 2024 | 75.50 Mn |
| Mar 31, 2023 | 24.69 Mn |
| Mar 31, 2023 | 24.69 Mn |
| Sep 30, 2022 | 25.00 Mn |
| Sep 30, 2022 | 25.00 Mn |